



You are entering a medical section of the Pfizer Landing Page.
All materials presented here are informative and they are not intended to be promotional.

Pfizer Oral Presentation

T Cell Re-directing Therapies in Relapsed/Refractory Multiple Myeloma

On Demand

Elranatamab (PF-06863135)

Abstract S192

MagnetisMM-1: Phase 1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific antibody, for patients with relapsed or refractory multiple myeloma (MM)*

Costello CL

[View Presentation](#)

Pfizer ePosters

All Poster sessions will be available to attendees for on-demand viewing.

The Virtual Congress platform closes on August 15, 2021.

Acute Lymphoblastic Leukemia – Clinical

Inotuzumab

EP353

A registry-based, observational safety study of inotuzumab ozogamicin (InO) treatment in patients (Pts) with B-cell precursor acute lymphoblastic leukemia (ALL) proceeding to hematopoietic stem cell transplant (HSCT)*

De Lima M

[View Presentation](#)

Inotuzumab

EP370

The patient experience of acute lymphoblastic leukemia and its treatment: a social media review

Morrison R

[View Presentation](#)

Chronic Myeloid Leukemia – Clinical

Bosutinib

EP671

Outcomes before and after dose reduction in patients with newly diagnosed chronic myeloid leukemia receiving bosutinib or imatinib*

Deininger M

[View Presentation](#)

Bosutinib

EP672

Second-line bosutinib for patients with chronic phase chronic myeloid leukemia: Final 10-year results of a phase 1/2 study*

Gambacorti-Passerini C

[View Presentation](#)

Bosutinib

EP684

The effect of body mass index on efficacy and safety of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia*

Brummendorf T

[View Presentation](#)

Myeloma and Other Monoclonal Gammopathies – Clinical

Elranatamab (PF-06863135)

EP1025

Overall, complete, and stringent complete response rates and minimal residual disease as potential surrogates for progression-free survival in newly diagnosed multiple myeloma

Daniele P

[View Presentation](#)

Elranatamab (PF-06863135)

EP1033

Overall and complete response rates as potential surrogates for overall survival in relapsed refractory multiple myeloma

Daniele P

[View Presentation](#)

Quality of Life, Palliative Care, Ethics and Health Economics

Bosutinib

EP1175

Quantifying patient preferences for tyrosine kinase inhibitors in chronic myeloid leukemia: a discrete-choice experiment*

Mason B

[View Presentation](#)

Publication Only

AML

PB1753

Uncertainty about the future: insights from older patients with acute myeloid leukaemia (AML) on different treatment paths

Walter R

Bosutinib

PB1520

Retrospective real-world comparison of clinical and economic burden between first-generation and second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML)*

Russell-Smith TA

Elranatamab (PF-06863135)

PB1667

The impact of COVID-19 on patient disease experience: insights from social media posts contributed

Crawford R

Elranatamab (PF-06863135)

PB1668

The patient experience of multiple myeloma: symptoms and health-related quality of life

Levy C

Elranatamab (PF-06863135)

PB1665

Multiple myeloma treatment decisions from the patient perspective

Lyll M

*Previously submitted abstract.

View additional Pfizer congress materials:

[PMI Congress Portal](#)